{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T07:06:54Z","timestamp":1776755214832,"version":"3.51.2"},"reference-count":55,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,6,22]],"date-time":"2023-06-22T00:00:00Z","timestamp":1687392000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>To investigate the effect and timing of subconjunctival bevacizumab injection on inhibiting corneal neovascularization (CorNV) in patients after chemical burns.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients with CorNV secondary to chemical burns were involved. Two subconjunctival injections of bevacizumab (2.5\u2009mg\/0.1\u2009mL per involved quadrant) with an interval of 4 weeks were administered, and followed up a year. The area occupied by neovascular vessels (NA), accumulative neovascular length (NL), mean neovascular diameter (ND), best-corrected visual acuity (BCVA) and intraocular pressure (IOP) were evaluated. Complication was also recorded.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Eleven patients with CorNV were involved. Eight patients had a history of surgery (four had amniotic grafts, one had keratoplasty, and three had amniotic grafts and keratoplasty). Decreasing in NA, NL, and ND were statistically significant at each time point compared to the baseline (<jats:italic>p\u2009&amp;lt;<\/jats:italic> 0.01). CorNV that developed within 1 month was considerably regressed, and vessels with fibrovascular membranes were found to be narrower and shorter than pretreatment. BCVA improved in five patients (from one to five lines), remained unchanged in five patients, and decreased in one patient compared to pretreatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Subconjunctival bevacizumab injection has a particular potential for the regression of CorNV, especially newly formed within 1 month in patients after chemical burns.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2023.1210765","type":"journal-article","created":{"date-parts":[[2023,6,24]],"date-time":"2023-06-24T02:30:41Z","timestamp":1687573841000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Successful regression of newly formed corneal neovascularization by subconjunctival injection of bevacizumab in patients with chemical burns"],"prefix":"10.3389","volume":"10","author":[{"given":"Wen-yan","family":"Peng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-wen","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-fang","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin-Bing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shi-you","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,6,22]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1016\/j.ophtha.2010.01.039","article-title":"Corneal neovascularization as a risk factor for graft failure and rejection after Keratoplasty an evidence-based Meta-analysis","volume":"117","author":"Bachmann","year":"2010","journal-title":"Ophthalmology"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.2353\/ajpath.2007.070172","article-title":"Dexamethasone inhibits interleukin-1beta-induced corneal neovascularization: role of nuclear factor-kappaB-activated stromal cells in inflammatory angiogenesis","volume":"171","author":"Nakao","year":"2007","journal-title":"Am J Pathol"},{"key":"ref3","first-page":"595","article-title":"Laser photocoagulation for corneal stromal vascularization","volume":"90","author":"Nirankari","year":"1992","journal-title":"Trans Am Ophthalmol Soc"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1016\/S0161-620(00)00355-9","article-title":"Fine needle diathermy occlusion of corneal vessels","volume":"41","author":"Pillai","year":"2000","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.ajo.2007.05.028","article-title":"Photodynamic therapy with verteporfin for corneal neovascularization","volume":"144","author":"Yoon","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.1167\/iovs.03-1380","article-title":"Inhibition of hemangiogenesis and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival","volume":"45","author":"Cursiefen","year":"2004","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1097\/01.ico.0000611440.32234.8f","article-title":"Subconjunctival bevacizumab for corneal neovascularization in herpetic stromal keratitis","volume":"27","author":"Carrasco","year":"2008","journal-title":"Cornea"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1097\/ICO.0b013e3181e458c5","article-title":"Subconjunctival injection of bevacizumab in the treatment of corneal neovascularization associated with lipid deposition","volume":"30","author":"Chu","year":"2011","journal-title":"Cornea"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1111\/j.1755-3768.2008.01399.x","article-title":"Therapeutic effect of subconjunctival injection of bevacizumab in the treatment of corneal neovascularization","volume":"87","author":"You","year":"2009","journal-title":"Acta Ophthalmol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1097\/ICO.0b013e318158f6ad","article-title":"Topical bevacizumab and ocular surface neovascularization in patients with stevens-Johnson syndrome","volume":"27","author":"Uy","year":"2008","journal-title":"Cornea"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1080\/02713680701799101","article-title":"Subconjunctival bevacizumab injection for corneal neovascularization in recurrent pterygium","volume":"33","author":"Bahar","year":"2008","journal-title":"Curr Eye Res"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.burns.2012.07.018","article-title":"The subconjunctival administration of bevacizumab inhibits corneal neovascularization effectively in the rabbit corneal alkali burn model","volume":"39","author":"Doganay","year":"2013","journal-title":"Burns"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1097\/ICO.0000000000000849","article-title":"Efficacy of Subconjunctival Aflibercept versus Bevacizumab for prevention of corneal neovascularization in a rat model","volume":"35","author":"Gal-Or","year":"2016","journal-title":"Cornea"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1159\/000499165","article-title":"Comparison of Subconjunctival Aflibercept and betamethasone for the treatment of formed corneal neovascularization in a rabbit model","volume":"62","author":"Eiger-Moscovich","year":"2019","journal-title":"Ophthalmic Res"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s00417-014-2851-8","article-title":"Three-year corneal graft survival rate in high-risk cases treated with subconjunctival and topical bevacizumab","volume":"253","author":"Dekaris","year":"2015","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v050.i12","article-title":"nparLD: an R software package for the nonparametric analysis of longitudinal data in factorial experiments","volume":"50","author":"Frank Konietschke","year":"2012","journal-title":"J Stat Softw"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"8718","DOI":"10.1167\/iovs.11-7871","article-title":"Corneal penetration of topical and subconjunctival bevacizumab","volume":"52","author":"Dastjerdi","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"6277","DOI":"10.1167\/iovs.09-4571","article-title":"The different effects of early and late bevacizumab (Avastin) injection on inhibiting corneal neovascularization and conjunctivalization in rabbit limbal insufficiency","volume":"51","author":"Lin","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.ajo.2007.11.003","article-title":"Inhibition of corneal neovascularization by subconjunctival bevacizumab in an animal model","volume":"145","author":"Papathanassiou","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1007\/s00417-009-1170-y","article-title":"Avastin use in high risk corneal transplantation","volume":"247","author":"Vassileva","year":"2009","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1167\/iovs.08-1997","article-title":"Subconjunctival injection of bevacizumab (avastin) on corneal neovascularization in different rabbit models of corneal angiogenesis","volume":"50","author":"Chen","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1136\/bjophthalmol-2012-302137","article-title":"Subconjunctival bevacizumab induces regression of corneal neovascularisation: a pilot randomised placebo-controlled double-masked trial","volume":"97","author":"Petsoglou","year":"2013","journal-title":"Br J Ophthalmol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1016\/j.jcrs.2007.07.012","article-title":"Subconjunctival bevacizumab for vascularized rejected corneal grafts","volume":"33","author":"Awadein","year":"2007","journal-title":"J Cataract Refract Surg"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1097\/ICO.0b013e31823f8d71","article-title":"Effects of subconjunctival bevacizumab on corneal neovascularization: results of a prospective study","volume":"31","author":"Benayoun","year":"2012","journal-title":"Cornea"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1001\/archopht.126.1.71","article-title":"Promotion of graft survival by vascular endothelial growth factor a neutralization after high-risk corneal transplantation","volume":"126","author":"Bachmann","year":"2008","journal-title":"Arch Ophthalmol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1097\/ICO.0b013e3181d92834","article-title":"Perilimbal bevacizumab injection for interface neovascularization after deep anterior lamellar keratoplasty","volume":"29","author":"Foroutan","year":"2010","journal-title":"Cornea"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s10792-014-9938-4","article-title":"Subconjunctival and\/or intrastromal bevacizumab injections as preconditioning therapy to promote corneal graft survival","volume":"35","author":"Fasciani","year":"2015","journal-title":"Int Ophthalmol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1001\/archophthalmol.2009.18","article-title":"Topical bevacizumab in the treatment of corneal neovascularization: results of a prospective, open-label, noncomparative study","volume":"127","author":"Dastjerdi","year":"2009","journal-title":"Arch Ophthalmol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"4807","DOI":"10.1167\/iovs.08-3148","article-title":"Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits","volume":"50","author":"Nomoto","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1136\/bjo.2005.066225","article-title":"Inflfluence of format on in vitro penetration of antibody fragments through porcine cornea","volume":"89","author":"Brereton","year":"2005","journal-title":"Br J Ophthalmol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1007\/s00417-007-0587-4","article-title":"Subconjunctival bevacizumab for corneal neovascularization","volume":"245","author":"Erdurmus","year":"2007","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.exer.2005.08.007","article-title":"A rabbit model for assessing the ocular barriers to the transscleral delivery of triamcinolone acetonide","volume":"82","author":"Robinson","year":"2006","journal-title":"Exp Eye Res"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1167\/iovs.07-0593","article-title":"Modeling of corneal and retinal pharmacokinetics after periocular drug administration","volume":"49","author":"Amrite","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/BF00141134","article-title":"Conjunctival and episcleral blood vessels are permeable to blood-borne horseradish peroxidase","volume":"24","author":"Raviola","year":"1983","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1002\/jps.20178","article-title":"Antibody pharmacokinetics and pharmacodynamics","volume":"93","author":"Lobo","year":"2004","journal-title":"J Pharm Sci"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1097\/ICO.0b013e31821c9b44","article-title":"A randomized controlled trial of intralesional bevacizumab injection on primary pterygium: preliminary results","volume":"30","author":"Enkvetchakul","year":"2011","journal-title":"Cornea"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1097\/ICO.0b013e3182151e0e","article-title":"Randomized controlled trial of subconjunctival bevacizumab injection in impending recurrent pterygium: a pilot study","volume":"31","author":"Lekhanont","year":"2012","journal-title":"Cornea"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/bjo.2011.204701","article-title":"Consensus statement on indications for anti-angiogenic therapy in the management of corneal diseases associated with neovascularisation: outcome of an expert roundtable","volume":"96","author":"Cursiefen","year":"2012","journal-title":"Br J Ophthalmol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1097\/ICO.0000000000002272","article-title":"Early application of Bevacizumab after Sclerocorneal grafting for patients with severe late-stage ocular chemical burns","volume":"39","author":"Huang","year":"2020","journal-title":"Cornea"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s004170050118","article-title":"Effect of 0.1% dexamethasone on epithelial healing in experimental corneal alkali wounds: morphological changes during the repair process","volume":"236","author":"Chung","year":"1998","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1159\/000111158","article-title":"Effects of acetylcysteine and dexamethasone on experimental corneal wounds in rabbits","volume":"40","author":"Sarchahi","year":"2008","journal-title":"Ophthalmic Res"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1080\/02713680802245772","article-title":"Inhibitory effect of oral doxycycline on neovascularization in a rat corneal alkali burn model of angiogenesis","volume":"33","author":"Dan","year":"2008","journal-title":"Curr Eye Res"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"C1358","DOI":"10.1152\/ajpcell.2001.280.6.C1358","article-title":"Role of vascular endothelial growth factor in regulation of physiological angiogenesis","volume":"280","author":"Ferrara","year":"2001","journal-title":"Am J Physiol Cell Physiol"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.ophtha.2005.11.019","article-title":"Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration","volume":"113","author":"Avery","year":"2006","journal-title":"Ophthalmology"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s00417-006-0466-4","article-title":"Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration","volume":"245","author":"Lazic","year":"2007","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1136\/bjo.2008.144410","article-title":"Systemic bevacizumab (Avastin) therapy for exudative neovascular age-related macular degeneration. The BEAT-AMD-Study","volume":"93","author":"Schmid-Kubista","year":"2009","journal-title":"Brit J Ophthalmol"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1097\/ICO.0b013e31820cd3f4","article-title":"Compensatory growth factor and cytokine response in tears after subconjunctival bevacizumab injection","volume":"30","author":"Jeong","year":"2011","journal-title":"Cornea"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1007\/s00417-009-1099-1","article-title":"Short-and long-term safety profile and efficacy of topical bevacizumab (Avastin) eye drops against corneal neovascularization","volume":"247","author":"Koenig","year":"2009","journal-title":"Graef Arch Clin Exp"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"e33","DOI":"10.1016\/j.ophtha.2008.02.013","article-title":"The effect of topical bevacizumab on corneal neovascularization","volume":"115","author":"Kim","year":"2008","journal-title":"Ophthalmology"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s00417-007-0684-4","article-title":"Bevacizumab (Avastin) eye drops inhibit corneal neovascularization","volume":"246","author":"Bock","year":"2008","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1097\/ICO.0b013e31818b8be0","article-title":"Evaluation of cytotoxic effects of bevacizumab on human corneal cells","volume":"28","author":"Chalam","year":"2009","journal-title":"Cornea"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1097\/ICO.0b013e3180de1d0a","article-title":"Safety profile of bevacizumab on cultured human corneal cells","volume":"26","author":"Yoeruek","year":"2007","journal-title":"Cornea"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1590\/S1807-59322011000800023","article-title":"The effect of subconjunctival bevacizumab on corneal neovascularization, inflammation and re-epithelization in a rabbit model","volume":"66","author":"Mello","year":"2011","journal-title":"Clinics (S\u00e3o Paulo)"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"4653","DOI":"10.1167\/iovs.08-2805","article-title":"Bevacizumab application delays epithelial healing in rabbit cornea","volume":"50","author":"Kim","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1136\/bjophthalmol-2011-300856","article-title":"Evaluation of corneal neovascularisation","volume":"95","author":"Faraj","year":"2011","journal-title":"Br J Ophthalmol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1210765\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,24]],"date-time":"2023-06-24T02:30:45Z","timestamp":1687573845000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1210765\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,22]]},"references-count":55,"alternative-id":["10.3389\/fmed.2023.1210765"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2023.1210765","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,22]]},"article-number":"1210765"}}